Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T08:20:10.150Z Has data issue: false hasContentIssue false
  • English
  • Français

Zuclopenthixol-Induced Neuroleptic Malignant Syndrome at Rechallenge and its Extrapyramidal Effects

Published online by Cambridge University Press:  02 January 2018

Charles J. F. Kemperman
Charles J. F. Kemperman*
Affiliation:
Department of Psychiatry, State University Hospital, POB 30.001, 9700 RB Groningen, The Netherlands
Get access Rights & Permissions [Opens in a new window]

Abstract

This is the first report of a zuclopenthixol-induced NMS. The lack of previous reports may be because the receptor-binding profile of thioxanthenes gives rise to fewer extrapyramidal effects than comparable neuroleptics. It is important to know more of the relationship between the potential for induction of extrapyramidal effects and success in NMS rechallenge.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 154 , Issue 4 , April 1989 , pp. 562 - 563
Copyright
Copyright © Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addonizio, G., Susman, V. L. & Roth, S. D. (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biological Psychiatry, 22, 1004–1020.Google Scholar
Heikkilä, L., Laitinen, J. & Vartiainen, H. (1981) Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients – a double-blind clinical multicentre investigation. Acta Psychiatrica Scandinavica, 64 (suppl. 294), 30–38.Google Scholar
Kellam, A. M. P. (1987) The neuroleptic malignant syndrome, so-called: a survey of the world literature. British Journal of Psychiatry, 150, 752–759.Google Scholar
Kuny, S. & Woggon, B. (1983) Cis(Z)-clopenthixol in the treatment of acute schizophrenia. Proceedings of symposium, 13th July, at VII World Congress of Psychiatry, (ed. Bernar, P.) pp. 15–24. Vienna: World Psychiatric Association.Google Scholar
Nordisk Dyskinesia Study Group (1986) Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology, 90, 423–429.Google Scholar
Snoek, J. W., van den Hoofdakker, R. H. & Haaxma, R. (1982) Het “maligne” neuroleptische syndroom. Nederlands Tijdschrift voor Geneeskunde, 126, 74–75.Google Scholar
Sullivan, C. F. (1987) A possible variant of the neuroleptic malignant syndrome. British Journal of Psychiatry, 151, 689–690.CrossRefGoogle ScholarPubMed
Verhoeven, W. M. A., & Elderson, A. (1985) Het maligne neuroleptica syndroom: een geslaagde behandeling van een patient met bromocriptine. Nederlands Tijdschrift voor Geneeskunde, 129, 76–78.Google Scholar
Verhoeven, W. M. A., Elderson, A. & Westenberg, H. G. M. (1985) Neuroleptic malignant syndrome: successful treatment with bromocriptine. Biological Psychiatry, 20, 680–684.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.